ABOS - NASDAQ
Acumen Pharmaceuticals, Inc.
$2.37
+2.6%Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
At a Glance
Live SnapshotAcumen Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Acumen Pharmaceuticals, Inc. Income Statement
ABOS • NASDAQ
| Acumen Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.4M | 1.7M | |
GROSS PROFIT | |||||||
(184K) | (0.0) | (0.0) | (0.0) | (12.3M) | (8M) | (8.6K) | |
-184K | 0.0 | 0.0 | 0.0 | -12.3M | -6.6M | 1.7M | |
OPERATING INCOME | |||||||
(123.8M) | (114M) | (61.1M) | (45.2M) | (7.3M) | (1.4M) | (9.5M) | |
(18.9M) | (20.2M) | (18.8M) | (12.9M) | (7.3M) | (1.4M) | (926K) | |
(104.9M) | (93.8M) | (42.3M) | (32.4M) | (12.3M) | (8M) | (8.6M) | |
-123.8M | -114M | -61.1M | -45.2M | -19.6M | -7.9M | -7.8M | |
PRE-TAX INCOME | |||||||
(4.2M) | (4.1M) | (581K) | (0.0) | (0.0) | (0.0) | (0.0) | |
3.2M | 10.2M | 10.2M | 2.4M | 84K | 1K | 45K | |
(0.0) | (0.0) | (0.0) | (0.0) | -12.3M | -8M | (0.0) | |
2.5M | 11.7M | 8.8M | 2.4M | -81M | 587K | -102K | |
-121.3M | -102.3M | -52.4M | -42.9M | -100.6M | -7.3M | -7.9M | |
NET INCOME | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -45K | |
-121.3M | -102.3M | -52.4M | -42.9M | -100.6M | -7.3M | -7.9M |
SEC Filings
ABOS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | March 26, 2026 | March 26, 2026 | ||
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your ABOS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.